
Aadrikaa Legal Services (ALS)- Law I Litigation I Arbitration
Date: 26.10.2026
Bombay HC: Trademark Registration Does Not Automatically Protect a Pharma Company from Infringement Proceedings

This Short Article has been prepared & written by Advocate Ravi Shekhar Jha-Delhi High Court, New Delhi. The views expressed are based on his interpretation of the law. He can be reached at his email id intelconsul@gmail.com .
The Bombay High Court granted Franco Indian Pharmaceuticals Pvt. Ltd. an interim injunction restraining Corona Remedies Pvt. Ltd. from using the mark STIMULET for pharmaceutical products, finding it deceptively similar to Franco Indianβs long-standing STIMULIV mark.
The dispute at a glance
The case concerned two pharmaceutical companies and competing marks:
- Franco Indian Pharmaceuticals: owner of STIMULIV, an Ayurvedic liver-related preparation sold as syrup and tablets.
- Corona Remedies: user of STIMULET, an allopathic product used in treatments relating to breast cancer disorders and infertility.
Although the medicines served different therapeutic purposes, the Court held that the similarity of the names created an unacceptable risk in the pharmaceutical context.
Why the Court found the marks similar
The Court treated similarity as the threshold issue. Visually, the two marks share the same dominant portion, βSTIMUL,β and differ only in their last two letters: βIVβ versus βET.β The Court concluded that this was not enough to create a reliable phonetic distinction, particularly in India, where English pronunciation may vary widely.
The Court also rejected the argument that the productsβ distinct uses eliminated the risk of confusion. Instead, it emphasized that even slight confusion should be avoided when medicines are involved, especially where one product concerns sensitive treatments such as cancer and infertility.
Franco Indianβs stronger prior rights
Franco Indian adopted STIMULIV on 28 June 1974 and obtained registration in 1976 for pharmaceutical preparations related to liver and allied disorders. Its mark was registered in Part A of the old trade mark register, which required distinctiveness.
The Court found prima facie evidence of sustained and substantial use:
- Invoices and documentation traced use of STIMULIV back decades.
- STIMULIV sales reached Rs. 1,311.70 lakhs in 2019β20.
- Franco Indianβs sales had continued without interruption and showed growth over time.
By contrast, Corona Remedies claimed adoption of STIMULET in 2010. Its own records showed a multi-year gap in use after 2011β12, before sales resumed. The Court noted that Coronaβs 2019β20 sales of approximately Rs. 346.51 lakhs were materially lower than Franco Indianβs sales.
This evidence supported Franco Indianβs claim to stronger goodwill, reputation, and common-law rights as the prior and continuous user.
Registration did not end the dispute
Corona Remedies argued that, because both marks were registered, Franco Indian could not pursue an infringement action. The Court rejected that position.
It held that a defendantβs registration does not bar an infringement suit. In a conflict between registered proprietors of similar marks, the Court may assess which party has better rights under common law, including priority, continuity of use, sales, and goodwill.
On those factors, the Court found that Franco Indianβs position was substantially stronger: it had earlier registration, earlier use by decades, continuous sales, and a stronger commercial presence.
A key inconsistency in Corona Remediesβ defence
Corona Remedies contended that βSTIMULβ or similar expressions were common to the trade. But it had also sought registration for STIMULET and asserted that its own mark was distinctive and capable of identifying its goods.
The Court found this position difficult to sustain. A party claiming distinctiveness for its own STIMULET mark could not persuasively deny the distinctiveness of the earlier STIMULIV mark on the basis that the shared element was generic or widely used.
The Courtβs order
The Court made Franco Indianβs interim application absolute and restrained Corona Remedies from using STIMULET in relation to pharmaceutical products. It also dismissed Corona Remediesβ application seeking rejection of Franco Indianβs plaint, finding no fraud, suppression, or material concealment.
No order as to costs was made.
What this decision means
The ruling reinforces the heightened caution applied to pharmaceutical trade marks. Differences in medical use, patient category, or prescription status may not defeat an injunction where the names are visually and phonetically close. In such disputes, priority of use, continuity, sales evidence, and goodwill can outweigh a later userβs registration of a similar mark.
Aadrikaa Legal Services is a trusted legal and regulatory support partner providing end-to-end legal solutions to law firms, corporate organizations, and businesses across India. We specialize in paralegal services, litigation support, tax and regulatory matters, delivering reliable, efficient, and result-oriented legal assistance.
Our services include comprehensive paralegal support, drafting and documentation, legal research, case management, litigation handling, and representation support across various judicial and quasi-judicial forums. We also assist in direct and indirect tax matters, customs, GST, corporate regulatory compliance, and legal advisory.
Source: Bombay High Court
Handy Download:
Write to us at office@aadrikaalaw.com
Tel: +91-11-4999 2707









